Stimulation of tyrosine phosphorylation and calcium mobilization by Fc gamma receptor cross-linking. Regulation by the phosphotyrosine phosphatase CD45.
The binding and subsequent cross-linking of murine IgG2a or human IgG to the Fc gamma R on the monocytic cell line THP-1 induced a rapid, dose-dependent increase in tyrosine phosphorylation of several proteins (a doublet centered around 110 kDa, and bands at 80, 60, and 52 kDa) and smaller increases in other proteins. This phosphorylation was accompanied by an increase in intracellular free Ca2+. The signaling required the cross-linking of the IgG, either through a biotin-avidin complex or with a F(ab')2 second antibody. Cross-linking of an F(ab')2 fragment of mAb 32.2 to Fc gamma RI (CD64) or an Fab fragment of mAb IV.3 to Fc gamma RII (CDw32) gave similar results to those observed with intact murine IgG2a or human IgG. Cross-linking of a F(ab')2 fragment of mAb 3G8 to Fc gamma RIII (CD16) had very little effect. Increases in both tyrosine phosphorylation and intracellular free Ca2+ were significantly reduced in a dose-dependent manner upon treatment of THP-1 cells with the tyrosine kinase inhibitors herbimycin-A, genistein, or erbstatin. Additionally, there was a marked inhibition of both Ca2+ mobilization and tyrosine phosphorylation when a F(ab')2 fragment of a mAb (T191) to the protein tyrosine phosphatase CD45, was co-cross-linked with either Hu-IgG, Mu-IgG2a, F(ab')2 anti-Fc gamma RI, or Fab anti-Fc gamma RII. Taken together these results suggest that signaling through Fc gamma RI (CD64) and Fc gamma RII (CDw32) in the monocytic leukemia cell line THP-1 gives rise to rapid tyrosine phosphorylation of several proteins followed by an increase in intracellular calcium. In addition, CD45 is able to inhibit the intracellular signaling when it is brought into close proximity to the Fc gamma R. This suggests that this transmembrane tyrosine phosphatase may regulate the stimulation of the cells through the Fc gamma R.
Rankin
B M
BM
Bristol-Myers Squibb Pharmaceutical Research Institute, Department of Cellular Immunology, Seattle, WA 98121.
Yocum
S A
SA
Mittler
R S
RS
Kiener
P A
PA
D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology; D016227:Benzoquinones; D002118:Calcium / Q000378:metabolism*; D002460:Cell Line; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000502:physiology; D007074:Immunoglobulin G / Q000502:physiology; D047029:Lactams, Macrocyclic; D017493:Leukocyte Common Antigens / Q000502:physiology*; D051379:Mice; D010766:Phosphorylation; D011809:Quinones / Q000494:pharmacology; D017452:Receptors, IgG / Q000502:physiology*; D017828:Rifabutin / Q000031:analogs & derivatives; D014443:Tyrosine / Q000378:metabolism*
D000911:Antibodies, Monoclonal; D016227:Benzoquinones; D007140:Immunoglobulin Fab Fragments; D007074:Immunoglobulin G; D047029:Lactams, Macrocyclic; D011809:Quinones; D017452:Receptors, IgG; D017828:Rifabutin; D014443:Tyrosine; C020754:herbimycin; D017493:Leukocyte Common Antigens; D002118:Calcium